Contineum Therapeutics Cash Flow Statement (2023-2025) | CTNM

Cash Flow Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Operating Activities
Net Income -4.82M41.57M-6.25M-7.77M-8.42M-9.01M-10.27M-14.56M
Share-based Compensation 0.49M0.49M0.48M0.76M0.77M1.49M2.29M2.25M2.57M2.42M2.57M
Gains from Investment Securities -0.01M0.40M0.57M2.88M-0.01M6.56M5.11M5.58M
Non-cash Items 14.89M27.02M1.93M39.02M2.11M2.21M2.62M19.86M
Cash from Operations -5.24M40.67M-5.38M-10.70M-7.97M-8.50M-6.17M-10.20M-14.41M-15.66M-12.20M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.26M0.22M1.00M1.20M1.02M1.07M0.78M1.06M0.28M0.41M0.00M
Amortization of Deferred Charges 0.03M-0.22M-0.00M
Depreciation & Amortization (CF) 0.07M0.04M0.04M0.04M0.06M0.06M0.06M0.12M0.08M0.08M0.08M
Change in Working Capital
Change in Account Payables 0.28M-0.31M0.66M-0.62M-0.07M0.17M0.66M0.38M1.83M-1.64M-1.22M
Change in Accured Expenses -0.98M2.15M2.02M-1.60M-0.38M-1.46M1.21M2.94M-2.86M-0.10M0.35M
Investing Activities
Capital Expenditures 0.05M0.03M0.02M0.31M0.15M0.12M0.08M0.17M0.05M0.04M0.10M
Change in Acquisitions & Divestments 18.62M14.15M12.60M31.34M39.52M30.23M42.28M45.13M48.65M39.37M33.68M
Cash from Investing Activities 9.36M-44.46M-39.50M9.03M8.73M-38.90M-30.18M-9.39M14.91M13.88M14.94M
Financing Activities
Other financing activities 0.01M0.01M0.00M0.00M0.14M
Debt Issuance and Repayment
Long-Term Debt Repayments 0.62M3.12M
Change in Capital Stock
Shares Issued 0.01M0.02M0.08M0.05M0.12M0.31M-108.06M108.06M0.02M0.24M
Preferred Shares Issued 10.24M
Misc.
Cash from Financing Activities -0.62M46.79M10.32M-0.32M-0.02M108.36M0.01M0.64M0.02M0.09M19.11M
Change in Cash 3.49M43.01M-34.55M-2.00M0.74M60.97M-36.34M-18.95M0.53M-1.69M21.85M
Beginning Cash Balance -3.49M-43.01M34.55M17.52M15.53M16.26M77.23M40.89M21.94M22.47M20.78M
Free Cash Flow -5.30M40.64M-5.40M-11.01M-8.12M-8.62M-6.25M-10.37M-14.46M-15.71M-12.29M
Net Cash Flow 3.49M43.01M-34.55M-2.00M0.74M60.97M-36.34M-18.95M0.53M-1.69M21.85M